The Lumella test estimates the concentration of Glycosylated Fibronectin, a new pregnancy specific biomarker to accurately assess the risk of preeclampsia.
The Lumella test requires a simple finger stick and can be performed in physician’s office/clinic in the first, second, or third trimesters, between 13 to 37 weeks of gestation.
Lumella Documents
Lumella Product Information Sheet CE
Lumella Quick Reference Guide
Quick Reference Guide Addendum
Lumella Reader User Guide
Lumella Patient Education:
Brochure 1 | Brochure 2 | Brochure 3
Diabetomics, Inc. is a global medical diagnostics company pioneering innovative, non-invasive point-of-care tests that are especially useful in alleviating the substantial economic and public health burden of maternal health and diabetes in low and middle income countries.
ADDRESS
Diabetomics, Inc.
2345 NE Overlook Dr.
Suite #140
Hillsboro, OR 97006
PHONE
503-924-5110
Toll-Free 877-748-9355
FAX
503-924-5111
CONTACT US